ClinicalTrials.gg
Not yet recruitingNCT06649656Updated Oct 21, 2024

A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors

A Phase 1 interventional study of TQB2252 injection in Advanced Cancers, sponsored by Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-21.

Sponsored by Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is a multicenter, single arm, and open design Phase I clinical trial aimed at evaluating the safety, Pharmacokinetics (PK) characteristics, immunogenicity, and preliminary efficacy of TQB2252 injection in subjects with advanced malignant tumors.

02

Conditions studied

  • Advanced Cancers
03

In context

Lead sponsor

Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subjects voluntarily joined this study, signed an form, and showed good compliance;
  • 18 years old ≤ 75 years old (calculated from the date of signing the informed consent form);
  • Electrocorticogram () score ranges from 0 to 1 points;
  • Expected survival is greater than 12 weeks;
  • Confirmed to have at least one according to 1.1 (solid tumor) or Lugano 2014 (lymphoma) criteria;
  • Late stage malignant tumor subjects who have failed standard treatment or lack effective treatment;
  • Women of childbearing age should agree to use effective measures during the study period and for 6 months after the end of the study; Men should agree to use effective contraceptive measures during the study period and for 6 months after the end of the study period.

Exclusion criteria

Exclusion Criteria:

  • Has experienced or currently has other malignant tumors within the past 5 years prior to the first use of medication;
  • There are multiple factors that affect diseases related to intravenous injection and venous blood collection;
  • The adverse reactions of previous anti-tumor treatments have not recovered to a (CTCAE) v5.0 score of ≤ 1;
  • Individuals who have undergone major surgical treatment, significant traumatic injury, or are expected to undergo major surgery during the expected study treatment period within 4 weeks prior to the first use of medication;
  • Subjects who experience any bleeding or bleeding events ≥ CTCAE grade 3 within 4 weeks prior to the first administration;
  • An arterial/venous thrombotic event occurred within 6 months prior to the first administration;
  • Active viral hepatitis with poor control;
  • Active syphilis infected individuals in need of treatment;
  • History of active pulmonary tuberculosis, idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonia, radiation pneumonitis requiring treatment, or clinically symptomatic active pneumonia;
  • Individuals with a history of abuse of psychotropic drugs who are unable to quit or have mental disorders;
  • Diagnosed with immunodeficiency or undergoing systemic therapy or any other form of therapy due to a history of hepatic encephalopathy;
  • Previously experienced grade 3 or higher adverse reactions related to immunotherapy;
  • Suffering from significant cardiovascular disease;
  • Active or uncontrolled severe infections;
  • Patients with renal failure requiring hemodialysis or peritoneal dialysis;
  • History of immunodeficiency, including positivity or other acquired or congenital immunodeficiency diseases;
  • Individuals with epilepsy who require treatment;
  • Previously received treatment with similar anti-lag3 drugs.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    TQB2252 injection

    This product is administered via intravenous infusion, with recommended doses of 600mg TQB2223 monoclonal antibody and 200mg penpulimab injection, administered once every 3 weeks.

    Drug: TQB2252 injection

Interventions

  • DrugTQB2252 injection

    TQB2252 injection is a compound preparation of TQB2223 monoclonal antibody (LAG-3) and penpulimab (PD-1), with a specification of 300mg TQB2223 monoclonal antibody and 100mg (20ml) penpulimab per bottle.

06

What researchers measure

Primary outcomes

  1. Adverse events (AE) rate

    The evaluation criteria for the nature and severity of adverse events are based on the National Cancer Institute's CommonTerminology Criteria for Adverse Events (NCI CTCAE version 5.0).

    Time frame: From date of the first dose until the date of 28 days after last dose or new anti-tumor treatment, whichever came first.

Secondary outcomes

  1. Time to reach maximum observed plasma concentration (Tmax)

    Time to reach maximum (peak) plasma concentration following drug administration

    Time frame: Day1 of Cycle1, Cycle3: within 30 minutes pre-dose, 0.25, 2, 4, 8, 24, 48, 168, 336 hour post dose. Day1 of Cycle2, Cycle4~Cycle 8: pre-dose. (Each cycle is 21 days)

  2. Maximum Plasma Concentration (Cmax)

    The Cmax is the maximum observed plasma concentration of TQB2252.

    Time frame: Day1 of Cycle1, Cycle3: within 30 minutes pre-dose, 0.25, 2, 4, 8, 24, 48, 168, 336 hour post dose. Day1 of Cycle2, Cycle4~Cycle 8: pre-dose. (Each cycle is 21 days)

  3. Elimination half-life (t1/2)

    Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.

    Time frame: Day1 of Cycle1, Cycle3: within 30 minutes pre-dose, 0.25, 2, 4, 8, 24, 48, 168, 336 hour post dose. Day1 of Cycle2, Cycle4~Cycle 8: pre-dose. (Each cycle is 21 days)

  4. Objective Response Rate (ORR)

    Defined as the percentage of Complete Response (CR) plus partial response (PR) assessed by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 criteria

    Time frame: up to 2 years

  5. Progression-free survival (PFS)

    Defined as the time from the first dose of TQB2252 to the first occurrence of disease progression or death from any cause.

    Time frame: up to 2 years

  6. Disease control rate (DCR)

    Defined as the proportion of subjects with CR, PR, or Stable Disease (SD).

    Time frame: up to 2 years

  7. Duration of Response (DOR)

    Defined as the time from first documented response to documented disease progression.

    Time frame: up to 2 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2024; primary completion for Nov 2026, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2024
First posted
Oct 21, 2024
StartEst.
Nov 2024
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2026
Last update
Oct 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06649656
Responsible party
Sponsor
First posted
Oct 21, 2024
Start date
Nov 2024 (estimated)
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 21, 2024

Study contacts

Xing Zhang, Doctor
Contact
zhangxing@sysucc.org.cn
13610223691
Qingqing Cai, Doctor
Contact
caiqq@sysucc.org.cn
13798101121

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion